BSE filing, NSE: CHEMCRUX. Summary written from the filing by ALFA Finder's alert engine.
Chemcrux Enterprises Ltd: key numbers
- Share price
- ₹82.30
- Market cap
- ₹121.9 Cr
- Revenue (annual)
- ₹80.65 Cr
- Net profit (annual)
- ₹3.73 Cr
- P/E (TTM)
- 29.4×Sector 34.5×
- Promoter holding
- 72.92%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chemcrux Enterprises Ltd
All →Chemcrux Enterprises Board Meeting Date
Chemcrux Enterprises intimated a Board Meeting scheduled for 02 November 2026 to approve unaudited financial results for Q2 and H1 FY2026-27. The trading window for insiders remains closed until 48 hours after results are published.
Chemcrux Enterprises Management Change
Chemcrux Enterprises Ltd regularised the appointment of Ms. Zarna Pankaj Thakar as an Independent Director for one year, effective August 4, 2026, per AGM approval.
Chemcrux Enterprises Annual General Meeting
Chemcrux Enterprises held its 30th Annual General Meeting on September 17, 2026. The meeting covered routine business, including financial statement approval and dividend declaration.
Chemcrux Enterprises Management Change
Mr. Bhanubhai Patel and Mr. Shailesh Patel have ceased to be Independent Directors of the Company following the completion of their second five-year tenure.
Chemcrux Enterprises Dividend
Chemcrux Enterprises Limited recommended a final dividend of Re. 1 per equity share for FY 2025-26. The payment follows the upcoming General Meeting.
Chemcrux Enterprises Other Announcement
Chemcrux Enterprises has fixed 10th September 2026 as the record date to ascertain eligibility for the final dividend to be declared at the 30th AGM.
Other other announcement announcements
All →eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.
Jhandewalas Foods Other Announcement
Jhandewalas Foods filed its quarterly shareholding pattern for the period ended September 30, 2026. The filing records holdings by category and contains no transaction or money event.